THRV-1268, a novel and potent SGK1 inhibitor, improved adverse cardiac remodeling beyond empagliflozin, an SGLT2 inhibitor, by reducing inflammation and fibrosis mechanisms in heart failure.
30 August 2025 (13:15 - 14:00)
Organised by: 
Slides
About the speaker
Massachusetts General Hospital - Harvard Medical School, Boston (United States of America)
3 More presentations in this session
Assistant Professor P. Kalaydzhiev (Sofia, BG)
Associate Professor V. Vintila (Bucharest, RO)
Access the full session
The Event
ESC Congress 2025
30 August 2025
13:15 CET
You may be interested in
Congress Session
Congress Session
